 |
|
|
| |
AASLD
The Liver Meeting
Boston MA
November 9-13 2019 |
| |
| |
- IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
- (07/12/23)
- Assessing the Real-World Effectiveness and
Clinical Efficacy of 8198 Patients Receiving
Elbasvir/Grazoprevir for the Treatment of HCV Infection
- (02/03/20)
- Changes in Insulin Resistance Out to 3 Years After
Successful Interferon-Free Treatment of Chronic HCV Infection - (01/13/20)
- Impact of Prescribed Treatment Duration on Hepatitis C Treatment Adherence: Comparison of 8- and 12-Week Treatment With Glecaprevir/Pibrentasvir - (01/13/20)
- Effect of Spatial Access on HCV Linkage to Care
In the US (2016) Based On Large Real-world Dataset - (01/13/20)
- Outcomes of Patients Interrupting Glecaprevir/Pibrentasvir Treatment: A Case Series From Clinical Trials - (01/13/20)
- Short duration sofosbuvir-velpatasvir is inferior to standard duration therapy in the treatment of recently acquired HCV infection: results from the REACT study - (12/06/19)
- Short duration sofosbuvir-velpatasvir is inferior to standard duration therapy in the treatment of recently acquired HCV infection: results from the REACT study - (12/06/19)
-
Mission possible: In Iceland 95% of eligible HCV infected patients were initated on treatment within three years. Results from the Treatment as Prevention for Hepatitis C (TraP HepC) program - (12/06/19)
- Italian real life experience of resistance guided retreatment in HCV infected patients who previously failed a NS5A inhibitor containing regimen - (12/06/19)
-
Salvage Therapy in Cancer Patients with Hepatitis C without
Sustained VirologicResponse after Direct-Acting Antivirals -A Prospective Study - (12/06/19)
-
8 weeks of Glecaprevir/pibrentasvir is effective and
well tolerated in non-GT3 HCV patients with cirrhosis - (12/20/19)
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With Chronic Hepatitis C Virus Genotypes 1-6 in Brazil - (12/20/19)
- Impact of Prior Tenofovir Disoproxil Fumarate Treatment Duration on Tenofovir Alafenamide Safety Profile in Virally Suppressed, Chronic HBV Patients Switched From TDF to TAF - (12/13/19)
- Zydus Announces Positive Results From EVIDENCES IV Phase 2
Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH - (12/13/19)
-
Tropifexor (TXR), an FXR Agonist for the Treatment of NASH - Interim Results from First Two Parts of Phase 2b Study FLIGHT-FXR - (12/13/19)
-
Effects of Cotadutide (MEDI0382) on Biomarkers of Nonalcoholic Steatohepatitis in Overweight or Obese Subjects with Type 2 Diabetes Mellitus: A 26-Week Analysis of a Randomized Phase 2b Study - (12/13/19)
- Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study - (12/12/19)
- LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study - (12/10/19)
- Safety and Efficacy at 48 Weeks After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients With Risk Factors for TDF Use - (12/10/19)
- Impact of Prior Tenofovir Disoproxil Fumarate Treatment Duration on Tenofovir Alafenamide Safety Profile in Virally Suppressed, Chronic HBV Patients Switched From TDF to TAF - (12/10/19)
-
LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study - (12/09/19)
- Higher Number of Concurrent Metabolic Co-Morbidities Is Associated with Increasingly Higher Risk of Significant Hepatic Fibrosis and Cirrhosis in Nonalcoholic Fatty Liver Disease Patients - (12/09/19)
-
MELD-score changes in relation to clinical outcome
following DAAs in HCV-infected patients with cirrhosis - (12/09/19)
-
Effects of Cotadutide (MEDI0382) on Biomarkers of Nonalcoholic Steatohepatitis in Overweight or Obese Subjects with Type 2 Diabetes Mellitus: A 26-Week Analysis of a Randomized Phase 2b Study - (12/09/19)
- Ongoing analysis of virologic control / functional cure of HBV and HDV infection following REP 2139-Ca and pegylated interferon alpha-2a therapy in patients with chronic HBV / HDV co-infection: 3.5-year follow-up results from the REP 301-LTF study - (12/05/19)
-
Ultrasound-based Controlled Attenuation Parameter (CAP) to Detect Longitudinal Changes in Liver Fat When Effect Size is Large -Experience From a Phase 2a, Dose-ranging Study Assessing MRI-Proton Density Fat Fraction (PDFF) and CAP In Parallel - (12/05/19)
- PF-05221304 (PF'1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCi), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT-Phase 2a, dose-ranging study - (12/05/19)
-
Safety and Efficacy of 10mg (high-dose) bulevirtide (Myrcludex B) in combination with PEG-IFNa or TDF in patients with chronic HBV/HDV co-infection: interim results. - (12/05/19)
- A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study - (12/05/19)
- THE IMPACT OF PRURITUS ON PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA) - (12/05/19)
-
Obeticholic Acid Treatment in Patients with Non-alcoholic Steatohepatitis: A Secondary Analysis of the REGENERATE Study Across Fibrosis Stages - (12/03/19)
-
Pilot Study of Add-on Peginterferon to Ongoing Nucleos(t)ide Analogues Therapy To Induce HBsAg Loss and To Investigate Mechanism of Action of Peginterferon - (12/03/19)
-
ASSESSMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA): RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL - (12/03/19)
- SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OBETICHOLIC ACID IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS OR CIRRHOSIS - (12/03/19)
-
Epidemiological Greek multicenter study of NAFLD: data from a large national cohort - (12/03/19)
- The Second-Generation Hepatitis B Virus (HBV) Core Inhibitor (CI) ABI-H2158 is Associated with Potent Antiviral Activity in a 14-Day Monotherapy Study in HBeAg-positive Patients with Chronic Hepatitis B (CHB) - (12/02/19)
- Continued Therapy with ABI-H0731 + NrtI Results in Sequential Reduction/Loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg-Positive Patients - (12/02/19)
- A novel liver-directed locked nucleic acid targeting PD-L1 expression reverts HBV-specific immune tolerance and induces sustained clearance of HBV infection - (12/02/19)
- LIVER-TARGETED INHIBITION OF PAPD5 AND PAPD7 LEADS TO SUSTAINABLE HBsAg REDUCTION IN THE AAV-HBV MOUSE MODEL - (12/02/19)
- Combination treatment of liver-targeted HBV locked nucleic acid antisense oligonucleotide and TLR7 agonist RO7020531 leads to a prolonged off-treatment anti-viral effect in the AAV-HBV mouse model - (12/02/19)
- Safety, pharmacokinetic, pharmacodynamics and viral data after 6-weeks of dosing with TLR7 agonist RO7020531 in chronic hepatitis B patients - (12/02/19)
- INTERIM RESULTS OF A PHASE 1 STUDY OF RO7062931: A NOVEL LIVER-TARGETED SINGLE-STRANDED OLIGONUCLEOTIDE (SSO) WITH LOCKED NUCLEIC ACID (LNA) THAT TARGETS HBV TRANSCRIPTS - (12/02/19)
- Validation of the Diagnostic Accuracy of Magnetic Resonance Elastography for the Detection of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis Across Multiple Phase 2 and 3 Clinical Trials - (11/26/19)
- Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort - (11/26/19)
- Higher Number of Concurrent Metabolic Co-Morbidities Is Associated with Increasingly Higher Risk of Significant Hepatic Fibrosis and Cirrhosis in Nonalcoholic Fatty Liver Disease Patients - (11/26/19)
-
Underestimation of Liver Disease in the Medicare Eligible Population - (11/25/19)
- HCV-RNA Is Readily Detectable in Nasal and Rectal
Fluids of HCV Patients with High Viremia - (11/25/19)
- Course of Cirrhosis Regression: Lessons From Patients With HCV Cirrhosis Following Successful Sofosbuvir-Based Treatment - (11/25/19)
- Prevalence and profile of non-alcoholic fatty liver disease in lean adults: Systematic review and meta-analysis - (11/25/19)
- The global prevalence of resistance-associated substitutions (RAS) in "unusual" HCV subtypes - (11/25/19)
- Factors Associated with Mortality in Lean, Overweight and Obese Patients with Non-alcoholic Fatty Liver Disease - (11/25/19)
- REAL-LIFE EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/VELPATASVIR/ VOXILAPREVIR FOR CHRONIC HEPATITIS C PATIENTS WITH PRIOR DAA FAILURE: FINAL RESULTS OF THE NAVIGATORE NETWORK - (11/20/19)
- Machine Learning Models Accurately Interpret Liver Histology in Patients With Nonalcoholic Steatohepatitis - (11/19/19)
- Innovative Machine Learning Tool Predicts
Who Might Have Non-Alcoholic Steatohepatitis - (11/19/19)
- Machine Learning Models Accurately Interpret
Liver Histology in Patients With Nonalcoholic Steatohepatitis - (11/19/19)
- Phase 2a, Randomized, Double-blind, Placebo-controlled Study of an Antisense Inhibitor (ISIS 505358) in Treatment-naïve Chronic Hepatitis B (CHB) Patients: Safety and Antiviral Efficacy - (11/19/19)
- Results after 12 weeks treatment of multiple doses of GSK3389404 in chronic hepatitis B subjects on stable nucleos(t)ide therapy in a phase 2a double-blind, placebo-controlled study - (11/19/19)
- Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B - (11/19/19)
- First Clinical Experience with RNA Interference-based Triple Combination Therapy in Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)ide Analogue - (11/19/19)
-
JNJ-64530440 (JNJ-0440), A Novel, Class N Capsid Assembly Modulator (CAM-N): Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Ascending Doses in Patients with Chronic Hepatitis B - (11/19/19)
-
Pharmacokinetics of Glecaprevir/Pibrentasvir in Children With Chronic HCV Infection: Interim Analysis of Part 2 of the DORA Study - (11/18/19)
- Hepatitis C Virus Reinfection After Successful Treatment with Direct Acting Anti-viral Therapy among MSM - (11/18/19)
-
Drug Use and Reinfection Following HCV Treatment With Elbasvir/Grazoprevir Among Patients Receiving Opioid Agonist Therapy: Final Results From the CO-STAR Study - (11/18/19)
-
Effectiveness of Sofosbuvir / Velpatasvir in
Treating Hepatitis C Virus Infection in a Real-world Setting - (11/18/19)
-
Strategic Treatment Optimizationon for HCV (STOPHCV-1): an open-label factorial randomised controlled trial of short duration therapy for chronic hepatitis C - (11/18/19)
-
CLINICAL AND VIROLOGICAL CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C AND FAILURE TO A GLECAPREVIR AND PIBRENTASVIR (G/P) TREATMENT IN REAL WORLD - (11/18/19)
-
Short duration sofosbuvir-velpatasvir is inferior to standard duration therapy in the treatment of recently acquired HCV infection: results from the REACT study - (11/18/19)
-
HCV Resistance Patterns in a Worldwide
Network of Cohorts of GT-3a infected patients - (11/18/19)
-
HCV cure by IFN-free DAAs is associated with
increased survival in patients with HCV-related HCC - (11/18/19)
-
PRIOR THERAPY WITH SOFOSBUVIR/VELPATASVIR ASSOCIATED
WITH REDUCED RESPONSE TO SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR:
RESULTS FROM A CANADIAN PROSPECTIVE REGISTRY - (11/18/19)
- Hepatitis Debrief
The Liver Meeting 2019 - (11/15/19)
-
Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C - (11/14/19)
- Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment - (11/14/19)
-
Antiviral treatment status and risk of renal and cardiovascular
outcomes in patients with chronic hepatitis C - (11/14/19)
- High Risk of Non-alcoholic Liver Disease Mortality in Patients With Chronic Hepatitis C With Illicit Substance Use Disorder - (11/14/19)
- Glecaprevir/Pibrentasvir is Effective and Well Tolerated in Hepatitis C Patients With Cirrhosis: Real-World Experience From the German Hepatitis C-Registry - (11/13/19)
-
Addressing Barriers to Hepatitis C Virus (HCV) Elimination: Real-World Outcomes in Historically Underserved Patients With Chronic HCV Infection Treated With Glecaprevir/Pibrentasvir - (11/13/19)
-
From Clinical Trials to Real-World Evidence: Similar Virologic Cure Rates and Safety Outcomes Following Treatment With Glecaprevir/Pibrentasvir Among Patients With Chronic Hepatitis C Virus Infection and Recent Drug Use - (11/13/19)
-
Safety and Efficacy of Velpatasvir, Sofosbuvir and Voxilaprevir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (11/13/19)
-
Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6 Infection and Compensated Cirrhosis: EXPEDITION-8 Complete Results - (11/13/19)
-
DAA REGIMENS ARE ASSOCIATED WITH SIGNIFICANT REDUCTION IN LIVER RELATED MORTALITY DRIVEN LARGELY BY HIGHER SVR RATES: RESULTS FROM THE ERCHIVES COHORT - (11/13/19)
-
Course of Cirrhosis Regression: Lessons From Patients With HCV Cirrhosis Following Successful Sofosbuvir-Based Treatment - (11/13/19)
-
SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR IN PEDIATRIC PATIENTS 6 TO < 18 YEARS OLD WITH CHRONIC HEPATITIS C INFECTION - (11/13/19)
-
Efficacy and Safety of Glecaprevir/Pibrentasvir in
Treatment-Naïve Adults With Chronic Hepatitis C Virus Genotypes 1-6 in Brazil - (11/13/19)
- Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019 - (11/09/19)
- Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019 - Gilead Press Release - (11/09/19)
|
|
| |
|
|
|
|
|
|
